iA Clarington Investments announces several fund name changes and the June 2025 distributions for Active ETF Series
Fund Name Changes
To make it easier for advisors and investors to navigate our product shelf, and to reinforce the value we place on our sub-advisory partnerships, iA Clarington is making the following name changes to funds managed by Agile Investment Management LLC, Loomis, Sayles & Company, L.P., and QV Investors Inc.:
Previous Name
New Name
IA Clarington Core Plus Bond Fund
IA Clarington Agile Core Plus Bond Fund
IA Clarington Floating Rate Income Fund
IA Clarington Loomis Floating Rate Income Fund
IA Clarington U.S. Dollar Floating Rate Income Fund
IA Clarington Loomis U.S. Dollar Floating Rate Income Fund
IA Clarington Canadian Small Cap Fund
IA Clarington QV Canadian Small Cap Fund
IA Clarington Canadian Small Cap Class
IA Clarington QV Canadian Small Cap Class
IA Clarington U.S. Equity Class
IA Clarington QV U.S. Equity Class
IA Clarington U.S. Equity Currency Neutral Fund
IA Clarington QV U.S. Equity Currency Neutral Fund
IA Clarington Global Equity Fund
IA Clarington QV Global Equity Fund
In addition to the above changes, the French name of the IA Clarington Agile Global Total Return Income Fund has been changed from Fonds IA Clarington Agile de revenu mondial à rendement global to Fonds IA Clarington Agile de revenu mondial à rendement total.
These changes were effective June 19, 2025.
Active ETF Series Distributions
Per-unit distributions are detailed below:
For more information about IA Clarington Active ETF Series, please visit iaclarington.com/ETF
About IA Clarington Investments Inc.
A subsidiary of Industrial Alliance Insurance and Financial Services Inc. – Canada's fourth-largest life and health insurance company – iA Clarington offers a wide range of investment products, including actively managed mutual funds, managed portfolio solutions, Active ETF Series and socially responsible investments. As of May 30, 2025, iA Clarington has over $22 billion in assets under management. For more information, please visit iaclarington.com
Commissions, trailing commissions, management fees, brokerage fees and expenses all may be associated with mutual fund investments, including investments in exchange-traded series of mutual funds. The information presented herein may not encompass all risks associated with mutual funds. Please read the prospectus before investing. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. The iA Clarington Funds are managed by IA Clarington Investments Inc. iA Clarington and the iA Clarington logo, iA Wealth and the iA Wealth logo, and iA Global Asset Management and the iA Global Asset Management logo are trademarks of Industrial Alliance Insurance and Financial Services Inc. and are used under license. iA Global Asset Management Inc. (iAGAM) is a subsidiary of Industrial Alliance Investment Management Inc. (iAIM).
The payment of distributions and distribution breakdown, if applicable, is not guaranteed and may fluctuate. The payment of distributions should not be confused with a Fund's performance, rate of return, or yield. Distributions paid as a result of capital gains realized by a Fund and income and dividends earned by a Fund are taxable in the year they are paid.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
4 days ago
- Cision Canada
Medical City Dallas Hospital Adopts Perimeter's Innovative OCT Imaging Technology for Surgery
Deployment follows participation in pivotal trial of Perimeter's next-gen technology with AI for breast-conserving surgeries TORONTO and DALLAS, July 2, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced today that Medical City Dallas Hospital, an award-winning 899-bed acute care hospital in the Dallas-Fort Worth area, has adopted the company's current S-Series OCT (optical coherence tomography) technology for high-resolution visualization of tissue microstructures during surgery. The move comes on the heels of the hospital's participation in the pivotal, randomized controlled trial of Perimeter's next-generation B-Series device, which combines proprietary artificial intelligence ("AI") technology with OCT, and is being evaluated by the U.S. Food and Drug Administration for use during breast-conserving surgeries in the United States. "We are incredibly proud to partner with Medical City Dallas Hospital and its team of surgeons, who are truly innovators in their field," said Perimeter CEO Adrian Mendes. "Working with Dr. DiPasquale and Dr. Anderson and the Medical City Dallas team, who used our B-Series in the randomized controlled pivotal trial, has been invaluable to advancing our next-generation product and we are pleased that they are adopting our commercially approved S-Series to potentially enhance margin visualization in the OR." Medical City Dallas Hospital is the latest U.S. hospital to adopt the S-Series OCT, as Perimeter continues to deploy the technology nationwide. Cleared by the U.S. Food and Drug Administration (FDA) in 2021 for a general tissue indication, S-Series OCT is a high-resolution technology that, unlike X-ray, magnetic resonance imaging (MRI), or ultrasound, can 'see' disease at the cellular level. It is optimized down to 2mm for identifying regions of interest in tissue microstructures, and features such as blood vessels, ducts, and glands, making it ideal for visualizing surgical margins. About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that was recently evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month. S-Series OCT Intended Use and Unapproved Uses The S-Series OCT is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization with image review manipulation software for identifying and annotating regions of interest. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, statements regarding the anticipated terms and jurisdictions of the Offering; securities offered thereunder; the timing of the Offering, including the anticipated Closing Date; use of proceeds from the Offering; fees anticipated to be paid to the Agent and terms thereof; regulatory and exchange approvals, including the listing of the common shares offered pursuant to the Offering on the TSXV, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Annual Information Form for the year ended December 31, 2024, which is available on Perimeter's SEDAR+ profile at and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws. Contacts Stephen Kilmer Investor Relations Direct: 647-872-4849 Email: [email protected] Susan Thomas Media Relations Direct: 619-540-9195 Email: [email protected] Adrian Mendes Chief Executive Officer Toll-free: 888-988-7465 (PINK) Email: [email protected] SOURCE Perimeter Medical Imaging AI Inc.
Cision Canada
25-06-2025
- Cision Canada
Sysmex Corporation Receives Health Canada License for the CN-3000™ & CN-6000™ Automated Blood Coagulation Analyzers Français
CHICAGO, June 25, 2025 /CNW/ -- Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and informatic solutions, announces that Sysmex has received Health Canada license for the automated blood coagulation analyzers CN Series: "Timely hemostasis testing is crucial for diagnosing patients suspected of suffering from bleeding or clotting disorders," said Dan Zortman, CEO of Sysmex America. "Sysmex's CN-Series was designed with smart workflow features and a small footprint to assist laboratories seeking to improve efficiency, accuracy, and patient care while also addressing workforce challenges and optimizing resource utilization." Sysmex CN-Series™ provides high throughput, fully automated hemostasis analyzers that are expandable to match the needs of different laboratories. Laboratories with high workloads may opt for the optional sampler that provides an expanded sample loading capacity. To learn more about the Sysmex CN-3000 and CN-6000 systems, as well as other hemostasis reagents and products that are designed with quality and efficiency in mind, visit About Sysmex America The combination of Sysmex America's new testing methods and innovative hematology, hemostasis, urinalysis, flow cytometry and informatic systems are transforming the future of healthcare and contributing to healthier lives. As Americas regional affiliate of Kobe, Japan-based Sysmex Corporation – a trusted global leader respected for optimizing the efficiency, operations and financial performance of clinical laboratories – it offers diagnostic products that equip patients and the healthcare professionals who treat them with the information needed to make decisions with greater trust and confidence. Forbes magazine named Sysmex one of the most innovative companies in the healthcare equipment and services category, and the Center for Companies That Care named Sysmex America to its "Honor Roll." Learn more about Sysmex America at
Cision Canada
25-06-2025
- Cision Canada
Segway Rolls Out E3 Electric Scooter in Best Buy Canada as Retail Partner Exclusive
The micromobility leader's most compact, portable and affordable 3rd generation e-scooter is now available for pre-order at $200 off MSRP. ARCADIA, Calif., June 25, 2025 /CNW/ -- Segway, recently named No. 1 in global electric kick-scooter (eKickScooter) sales with more than 13 million sold worldwide, today announces pre-orders are open on the all-new E3 electric scooter through exclusive retail partner, Best Buy Canada. Customers can reserve the latest in the brand's popular entry-level E-Series for only $499.99 CAD ($699.99 MSRP) at or more than 90 retail locations across Canada now through the official release date of July 18 when it will be in-stock and full price. The E3 will also be available later this summer via Segway's official Canadian webstore at "We're redefining entry level electric scooters with the new E3," said Tom Hebert, VP of sales at Segway. "Not only are you getting our most portable, lightweight transportation solution that makes commuting and storage easy for everyone, you're getting fantastic features and performance coupled with legendary Segway quality at an incredible price. We're excited to be able to make the E3 available nationwide in Canada and through a trusted retail partner like Best Buy." The E3 has been redesigned for a more compact folded footprint and weighs in at only 16.4 kilograms thanks to an all-new aerospace-grade magnesium frame optimized for the perfect balance of weight and durability. This makes it the perfect last-mile companion, especially if the commute involves carrying it onto public transportation, up stairs or on an elevator. And even at an outstanding entry-level price, it offers an incredibly smooth ride with elastomer suspension, front and rear. Sporting an 800-Watt motor, it's capable of a 25 km/h max speed and can go up to 45 kilometers on a single charge thanks to SegRange™ range optimization. It's also packed with premium Segway technology to enhance safety and convenience like Apple Find My capability, SegRide stability enhancement and traction control. A 4-Watt headlight, turn signals and 256 RGB ambient lighting also ensure riders can see and be seen in low-light conditions. It's all wrapped together by a clean, streamlined silhouette, accented by minimalist lines and signature red details, reflecting a harmonious balance between form and function. The E3 represents a fresh take on entry-level alternative transportation that makes every ride easy. With its beginner-friendly approachability and lightweight frame, it's an excellent option for both first-timers looking for an affordable ride as well as seasoned commuters looking for the most portable scooter from a trusted brand. E3 FEATURES & SPECS E3 MEDIA KIT "We're excited to partner with Segway as the exclusive retailer for the E3," said Jeremy Carson, senior category leader at Best Buy Canada. "The E3 is perfect for customers seeking a compact electric scooter for urban commutes. We look forward to offering this high-quality entry-level option to Canadians." The E3 is the most recent of Segway's third generation electric scooter lineup, following the Best Buy Canada exclusive Segway F3 Pro. Other recent releases include the Segway F3, GT3 SuperScooter and flagship MAX G3 commuter scooter. The Segway E3 electric scooter is currently available through Best Buy Canada for only $499.99 CAD on pre-order now through July 18 ($699.99 MSRP). About Segway Segway transformed micromobility in 1999 with the revolutionary Personal Transporter, igniting global curiosity about the future of personal transportation. With a mission of "Simply Moving," Segway is dedicated to simplifying how people and goods move, improving efficiency and enhancing the overall experience of everyday life. For decades, Segway has continuously set new benchmarks in short-distance transportation and consumer robotics, constantly pushing the boundaries of innovation. Today, as the global leader in micromobility solutions, Segway's offerings have evolved far beyond its origins. From e-scooters and GoKarts to e-bikes, powersports vehicles and personal robots, Segway is pioneering the future of mobility with breakthrough technology, delivering innovative products that redefine the way we move. Discover more at About Best Buy A wholly owned subsidiary of Best Buy Co., Inc. (NYSE:BBY), Best Buy Canada Ltd. is one of Canada's largest and most innovative omnichannel retailers, operating the Best Buy, Best Buy Mobile, Best Buy Express and Geek Squad ( brands. With over 320 Best Buy, Best Buy Mobile and Best Buy Express stores across Canada and an expanded assortment of lifestyle products offered through Best Buy is a leader in total retail, catering to customers how, when, and where they want to shop. Best Buy Canada is committed to making a positive impact in the community with programs and partnerships that support youth to connect with technology to advance their education. For more information, visit
